

Apposite Capital Raises £144.5 million of New Capital

Firm promotes Valerie Auffray to Head of Investor Relations & Operations and Anne-Laure Meynier to Investment Director

London, UK – 12 June 2018. Apposite Capital, the private equity firm with an exclusive focus on healthcare, today announces that it has successfully raised £144.5m of capital for Apposite Healthcare Fund II and associated vehicles (the “Fund”).

Apposite received strong support from existing investors and a well-diversified group of new investors comprising fund of funds, financial institutions, family offices, endowments, foundations and corporates from Europe, Asia and the US.

Apposite Capital is dedicated solely to healthcare investment and operates at the small end of the private equity market. It has been successful in building market leaders since 2006 providing both capital and expertise to healthcare businesses in the UK and Europe. Typically, Apposite seeks to deploy £10-20 million over the life of an investment with a preference for taking majority shareholdings. As a result of a strong pipeline, the Fund has already made five investments: Medical Imaging Partnership, MC Care Holdings, NIMGenetics, Swanton Care & Community and OrthoD Group.

Commenting on the fundraising, David Porter, Managing Partner, Apposite Capital said: “We are grateful for the support received from existing and new investors. It reflects the quality of our team and track record as well as investors’ growing appetite for specialist sector focused managers. We look forward to further deploying the Fund and to providing growth and small buyout capital to healthcare businesses in the UK and Europe with high growth potential.”

Valerie Auffray and Anne-Laure Meynier have also been promoted to Head of Investor Relations & Operations and Investment Director, respectively.

Valerie Auffray joined Apposite Capital in 2008. She is responsible for fundraising, investor relations, funds reporting, marketing, as well as the firm’s operations.

Anne-Laure Meynier joined the firm in 2015 and is involved in all aspects of the investment process from originating to executing and managing investments. She serves as a director of NIMGenetics and is an observer on the Swanton Care & Community board.

The fundraising was led by the Apposite Capital in-house team, with TMR Strategic LLP as lead placement agent. Macfarlanes acted as legal advisor and Intertrust as Fund administrator.

- END -

Media contact:

Valerie Auffray

Tel: +44(0) 20 3475 1710

Email: valerie.auffray@appositecapital.com

About Apposite Capital

www.appositecapital.com

Apposite Capital is an independent investment firm focused exclusively on healthcare. It focuses on companies operating in healthcare services, social care services, medical products, pharmaceuticals and pharmaceutical services and digital health.

The firm operates at the small end of the private equity market, providing both capital and expertise to those businesses offering 'disruptive' models that aim to improve or reduce the cost of care provision and which have the potential to become market leaders.

Apposite has an in-depth sector knowledge covering key aspects of the healthcare industry internationally coupled with local insights, an exceptional network and an entrepreneurial mindset which it applies to drive the growth of its portfolio companies.

Apposite was established in 2006 and is headquartered in London, UK.

Apposite Capital LLP takes data privacy very seriously, and all reasonable care is taken to comply with the requirements of the EU General Data Protection Regulation ("GDPR"). For further information please see our [Data Protection Privacy Notice](#).